8-K: Veradigm Inc. to Transition to OTC Expert Market After Nasdaq Delisting

Veradigm Inc. will move to the OTC Expert Market after being delisted from the Nasdaq, with trading suspended on February 29, 2024.

Summary

• Veradigm Inc. received a notice from Nasdaq on February 27, 2024, stating that its common stock would be delisted.
• Trading of Veradigm's common stock was suspended on Nasdaq effective February 29, 2024.
• The company's shares will now be quoted on the OTC Expert Market, retaining the ticker symbol MDRX.
• As of February 29, 2024, Veradigm had 108,398,418 shares of common stock outstanding.

Sentiment

Score: 3

Explanation: The delisting from Nasdaq is a significant negative event, indicating potential financial or compliance issues. The move to the OTC market is generally viewed as a negative development for a company.

Positives

• Veradigm will retain its existing ticker symbol (MDRX) on the OTC Expert Market, which may provide some continuity for investors.

Negatives

• The delisting from Nasdaq is a significant negative event for the company and its shareholders.
• The move to the OTC Expert Market may reduce the visibility and liquidity of the company's stock.

Risks

• The delisting from Nasdaq could negatively impact investor confidence and the company's ability to raise capital in the future.
• Trading on the OTC Expert Market may be less liquid and more volatile than trading on Nasdaq.
• The company's future performance is subject to risks and uncertainties as detailed in their SEC filings.

Future Outlook

The company's future trading activity will be on the OTC Expert Market, and this is subject to risks and uncertainties as detailed in their SEC filings.

Management Comments

• Veradigm management stated that the company will retain its existing ticker symbol (MDRX) on the OTC Expert Market.

Industry Context

Delisting from a major exchange like Nasdaq is a significant event that can impact a company's valuation and investor perception, often leading to increased scrutiny and potential challenges in accessing capital markets. This move to the OTC Expert Market is not uncommon for companies facing compliance issues or other challenges.

Comparison to Industry Standards

• Companies that are delisted from major exchanges like Nasdaq often face challenges in maintaining investor confidence and liquidity.
• The move to the OTC Expert Market is a common path for companies that do not meet the listing requirements of major exchanges.
• Compared to companies listed on major exchanges, Veradigm may experience reduced trading volume and potentially higher volatility on the OTC Expert Market.

Stakeholder Impact

• Shareholders will experience a change in trading venue from Nasdaq to the OTC Expert Market.
• The delisting may negatively impact shareholder value and confidence.
• Employees may experience uncertainty due to the company's change in listing status.

Next Steps

• Veradigm's shares will begin trading on the OTC Expert Market.

Key Dates

Keywords

delisting, OTC Expert Market, Nasdaq, MDRX, common stock, trading suspension, Veradigm